HomeNDC LookupDrug shortages › Caspofungin Acetate Injection

Caspofungin Acetate Injection shortage

Caspofungin Acetate Injection is currently listed in shortage by the FDA. The FDA lists 3 affected products. This page was last refreshed from FDA data on Sep 19, 2026.

To Be Discontinued ⚠ Supply risk: High Anti-Infective 3 products 2 manufacturers 250 days First posted Jan 12, 2026 Updated Jun 30, 2026
Here’s the bottom line

Both Sandoz and Fresenius Kabi are permanently stopping production of their caspofungin acetate injection. Other makers — including those supplying Cancidas (caspofungin acetate) — have not reported a shortage, so the medicine remains listed from other sources.

Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).

Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →
3
Affected NDCs
2
Reporting manufacturers
0/2
Reporting mfrs supplying
0/2
Affected strengths supplied
250
Days in shortage
146
Medicaid Rx (2025)
Source: FDA Drug Shortages Database API (openFDA). Last refreshed Sep 19, 2026 · today

What’s in shortage — at a glance

These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Caspofungin Acetate Injection. Other makers that haven’t reported a problem are shown in the green card below.

Availability of affected NDCs
From the FDA shortage report
3 NDCs
To be discontinued 3
Affected strengths still supplied
Among manufacturers reporting this shortage
0/2 strengths
No supply 2
FDA-reporting manufacturers with supply
Among manufacturers reporting this shortage
0/2 makers
No supply 2
✓ Other manufacturers not reporting a shortage
Still-marketed Caspofungin Acetate Injection from companies that have not filed an FDA shortage — these are not counted in the figures above. Stock can still vary by pharmacy.
Merck Sharp & Dohme LLC Sagent Pharmaceuticals Fresenius Kabi USA, LLC Fosun Pharma USA Inc.
See all other options & details →
Shortage timeline
  1. Jun 30, 2026
    Currently in shortage
    3 of 3 products affected.
  2. Jun 30, 2026
    More presentations reported
    2 more products added to the shortage.
  3. Jan 12, 2026
    First reported to the FDA
    1 product first listed.

Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.

What exactly is on backorder — by manufacturer

Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 1 NDC click to expand
Status NDC / product Strength Availability Related information Reason
To Be Discontinued Caspofungin Acetate, Injection, 7 mg/1 mL (NDC 63323-358-10) NDC 63323-0358-10 Discontinuation of the manufacture of the drug
Manufacturer: Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.) 📞 Sandoz: 800-525-8747 2 NDCS click to expand
Status NDC / product Strength Availability Related information Reason
To Be Discontinued Caspofungin Acetate, Injection, 7 mg/1 mL (NDC 0781-3423-94) NDC 00781-3423-94 Marketed by Sandoz, Inc.; Discontinuation of the manufacture of the drug
To Be Discontinued Caspofungin Acetate, Injection, 5 mg/1 mL (NDC 0781-3421-94) NDC 00781-3421-94 Marketed by Sandoz, Inc.; Discontinuation of the manufacture of the drug

These rows are manufacturer reports to the FDA for Caspofungin Acetate Injection — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Caspofungin Acetate Injection? options further down this page.

Why is Caspofungin Acetate Injection in shortage?

The manufacturers listed in this report — Jiangsu Hengrui Pharmaceuticals (marketed by Sandoz, Inc.) and Fresenius Kabi USA — have each reported that they are permanently stopping production of their versions of caspofungin acetate injection. This affects two specific liquid concentrations: the 5 mg/1 mL strength (NDC 0781-3421-94, Sandoz/Hengrui) and the 7 mg/1 mL strength (NDC 0781-3423-94 from Sandoz/Hengrui and NDC 63323-358-10 from Fresenius Kabi). No specific public reason was shared by any of these manufacturers for why they made this decision — just that they are discontinuing manufacture of these products.

It's worth knowing that this report only covers these particular manufacturers and their specific products. No information was provided suggesting that any of these companies will continue making any version of this drug going forward.

Based on the manufacturer-reported reason(s) and notes on file with the FDA for Caspofungin Acetate Injection, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.

What should I do if I take Caspofungin Acetate Injection?

Caspofungin Acetate Injection is currently on the FDA shortage list. This is an antifungal medicine given by injection, and I want to walk you through what the current report shows.

Both strengths on this record — the 5 mg/1 mL and the 7 mg/1 mL — have no available source from the manufacturers who filed this report. The reason listed for both is that the maker is discontinuing production, so for these specific products the supply problem may be permanent rather than temporary. Because this is a discontinuation, talking with your prescriber or pharmacist is the right next step.

Keep in mind this report reflects only the manufacturer(s) who filed it. The same medicine is still listed as available from other makers, so this does not mean caspofungin is gone everywhere.

Here is what I suggest:

  • Do not stop, skip, or change your treatment on your own — this medicine is used for serious infections.
  • Ask your pharmacy whether the same medicine from another maker can be sourced. Options in our records include Cancidas (Merck), and caspofungin acetate from Sagent, Fresenius Kabi, and Fosun Pharma — though these may not be in local stock.
  • Ask your prescriber or pharmacist about a clinician-chosen alternative if your product cannot be found.

Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle these calls. This is general national data and may not match your local pharmacy's stock.

See “Where else can I get Caspofungin Acetate Injection?” below ↓ The same medicine from manufacturers not reporting a shortage, alternative dosage forms, and therapeutic equivalents with pricing.
If you are a patient:
  • Don’t stop or change the medication on your own — talk to your prescriber first.
  • If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
  • Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
  • Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Keep reading
Our full Caspofungin Injection guide

Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.

Read the Caspofungin Injection guide →

Where else can I get Caspofungin Acetate Injection?

FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Caspofungin Acetate Injection is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.

Same medicine, other manufacturers (not reported short)

Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from makers that have not filed a shortage with the FDA:

ProductStrengthForm / routeManufacturerNDC
Cancidas CASPOFUNGIN ACETATE 5 mg/mL Injection, Powder, Lyophilized, For Solution · Intravenous Merck Sharp & Dohme LLC 00006-3822-10
Cancidas CASPOFUNGIN ACETATE 7 mg/mL Injection, Powder, Lyophilized, For Solution · Intravenous Merck Sharp & Dohme LLC 00006-3823-10
Caspofungin Acetate CASPOFUNGIN ACETATE 5 mg/mL Injection, Powder, Lyophilized, For Solution · Intravenous Sagent Pharmaceuticals 25021-0194-10
Caspofungin Acetate CASPOFUNGIN ACETATE 7 mg/mL Injection, Powder, Lyophilized, For Solution · Intravenous Sagent Pharmaceuticals 25021-0195-10
Caspofungin Acetate CASPOFUNGIN ACETATE 5 mg/mL Injection, Powder, Lyophilized, For Solution · Intravenous Fresenius Kabi USA, LLC 63323-0356-10
Caspofungin Acetate CASPOFUNGIN ACETATE 5 mg/mL Injection, Powder, Lyophilized, For Solution · Intravenous Fosun Pharma USA Inc. 72266-0106-01
Caspofungin Acetate CASPOFUNGIN ACETATE 7 mg/mL Injection, Powder, Lyophilized, For Solution · Intravenous Fosun Pharma USA Inc. 72266-0107-01
Therapeutic equivalents & pricing 14 productsclick to expand

Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.

ProductManufacturerPackageNADAC $/unitAB ratingAvailability
Cancidas 7 mg/mLNDC 00006-3823-10 Merck 1 vial FDA listed
Caspofungin Acetate 7 mg/mLNDC 00781-3423-94 Sandoz 1 vial FDA listed
Caspofungin Acetate 7 mg/mLNDC 25021-0195-10 Sagent 1 vial AP FDA listed
Caspofungin Acetate 7 mg/mLNDC 63323-0358-10 Fresenius 10 vials AP FDA listed
Caspofungin Acetate 7 mg/mLNDC 65897-0004-01 Hangzhou 1 vial AP FDA listed
Caspofungin Acetate 7 mg/mLNDC 68083-0159-01 Gland 1 vial AP FDA listed
Caspofungin Acetate 7 mg/mLNDC 72266-0107-01 Fosun 1 vial AP FDA listed
Cancidas 5 mg/mLNDC 00006-3822-10 Merck 1 vial FDA listed
Caspofungin Acetate 5 mg/mLNDC 00781-3421-94 Sandoz 1 vial FDA listed
Caspofungin Acetate 5 mg/mLNDC 25021-0194-10 Sagent 1 vial AP FDA listed
Caspofungin Acetate 5 mg/mLNDC 63323-0356-10 Fresenius 10 vials AP FDA listed
Caspofungin Acetate 5 mg/mLNDC 65897-0002-01 Hangzhou 1 vial AP FDA listed
Caspofungin Acetate 5 mg/mLNDC 68083-0158-01 Gland 1 vial AP FDA listed
Caspofungin Acetate 5 mg/mLNDC 72266-0106-01 Fosun 1 vial AP FDA listed

Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.

Other drugs in the same treatment class

These are different medicines — not other versions of Caspofungin Acetate Injection — that fall in the same broad treatment class (antifungal antibiotics) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.

Identity & classification

GCN Seq No 047689
GCN 12613
HICL code 021909
Ingredient (HICL) Caspofungin Acetate
HIC1 code W
Therapeutic class — broad (HIC1) Anti-Infecting Agents
HIC2 code W3
Therapeutic class — intermediate (HIC2) Antimycotics
HIC3 code W3A
Therapeutic class — specific (HIC3) Antifungal Antibiotics
AHFS code 08:14.16.00
AHFS class Echinocandin Antifungals
FDB label name CASPOFUNGIN ACETATE 70 MG VIAL
FDB brand name Caspofungin Acetate
Legend status F — Federal legend — prescription drug or device
GPI-1411500025102130
GPI classCaspofungin Acetate
Where does this data come from?
Identity codes come from First Databank (FDB) (HICL ingredient, HIC1–3 therapeutic-class hierarchy, GCN, AHFS class, legend status) and Medi-Span GPI, mapped from a representative affected NDC. Licensed reference data — for identification only.

Other anti-infective shortages

Caspofungin Acetate Injection shortage FAQs

Is Caspofungin Acetate Injection in shortage?
Yes — the FDA currently lists Caspofungin Acetate Injection in shortage (status: “To Be Discontinued”, first reported Jan 12, 2026). 3 of 3 products are affected. This is national, manufacturer-reported data, so your pharmacy may still have stock.
Which products are affected?
Caspofungin Acetate, Injection, 7 mg/1 mL (NDC 63323-358-10) (NDC 63323-0358-10); Caspofungin Acetate, Injection, 7 mg/1 mL (NDC 0781-3423-94) (NDC 00781-3423-94); Caspofungin Acetate, Injection, 5 mg/1 mL (NDC 0781-3421-94) (NDC 00781-3421-94). The full per-NDC list (availability, manufacturer and status) is in the table above — each NDC links to its own page.
When will Caspofungin Acetate Injection be available again?
The FDA does not publish a guaranteed restock date, and no estimated-recovery note is on file. Availability can change daily — confirm with your pharmacy.
Can I still get Caspofungin Acetate somewhere?
Other manufacturers (Merck Sharp & Dohme LLC, Sagent Pharmaceuticals, Fresenius Kabi USA, LLC and others) still market it and have not reported a shortage. See “Where else can I get Caspofungin Acetate Injection?” above — stock still varies by pharmacy.
What should I do if I take Caspofungin Acetate Injection?
Don’t stop or change it on your own. Ask your pharmacist whether they can order it from another manufacturer or a different strength/package size, and ask your prescriber about a long-term plan before your supply runs out.

Still have a question about the Caspofungin Acetate Injection shortage?

Ask a pharmacist about this shortage →
How to read the Supply-Risk rating
Low (1–2)Multiple manufacturers still supplying and most strengths or pack sizes sourceable.
Medium (3)Some constraint — fewer suppliers or a notable share of NDCs unavailable.
High (4–5)Down to a single source, most strengths or pack sizes unsourceable, or a long-running outage.
Where does this data come from?
Shortage records come from the FDA Drug Shortages Database API via openFDA (/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.
Data structure & sourcing designed and verified by Dr. Brian Staiger, PharmD.
← Back to all current drug shortages